

Paraneoplastic Autoantibody Evaluation (PAVAL & PAC1) Discontinued

*Notification Date: August 6, 2026
Effective Date: Immediately*

To optimize test utilization and patient care, Mayo recommends that physicians order a comprehensive autoimmune/paraneoplastic evaluation based on the patient's clinical presentation. Traditional, underpowered paraneoplastic evaluations can lead to false-positive results or missed diagnoses.

RECOMMENDED ALTERNATIVES:

Orderable in Epic:

Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid or Serum ENC2 (LAB1866) / ENS2 (LAB1867)

- Most appropriate evaluation when PAVAL or PAC1 would have been considered for suspected central nervous system (CNS) immune-mediated disorders.

Build in process, order as Unlisted Lab Test:

AIAES | Axonal Neuropathy, Autoimmune/Paraneoplastic Evaluation, Serum

- Most similar to PAVAL when it comes to antibodies included, and an appropriate alternative when PAVAL would have been considered for peripheral nervous system (PNS) immune-mediated disorders.

MDC2/MDS2 | Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid or Serum

- Our most comprehensive neuroimmunology evaluation; recommended for patients suspected of having immune-mediated movement disorders only, such as ataxias.

DYS2 | Dysautonomia, Autoimmune/Paraneoplastic Evaluation, Serum

- Includes acetylcholine receptor ganglionic (alpha-3) antibody testing and is most useful for investigating idiopathic dysautonomic symptoms.

PCDEC/PCDES | Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Spinal Fluid or Serum

- Specifically designed for patients 18 years old and younger suspected of immune-mediated neurological disorders.